-Will cost ~4M annually to "moth ball" facility till get ready for GALNS production around 2015.
-Paid 50 million but think would cost 200-250 million to build. Think got cheap because of Wyeth acquisition (Wyeth had another plant there).
-Tax rate in Ireland ~12.5% (vs. 30's in US) so in couple years tax saving alone could pay for it.
-If facility used for GALNS could produce product for ~500 million/annual revenue (existing facilities and when current validation done expected by end of year would have ~1 Billion capacity so 1.5 Billion total).
-Facility has capability to be expanded to double capacity. No plans to do so at this time. Not clear if cheaper to do so or acquire other facility.
-GALNS trial looks good so far got about 1/2 sites initiated (don't recall exactly so may be off). Phase I/II patients still on therapy look good and plan to update during Q2 call in July.
-Facility could be modified to produce other products (e.g. Naglazyme/Aldurazyme) if necessary. Think process would take 12-18months (not sure exact going by memory). Changed process for Naglqazyme already so think can do so without running into problems of others (i.e. Genzyme).
Recent BMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:48:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:43:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 12:30:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2026 11:55:45 PM
- BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics M • PR Newswire (US) • 03/12/2026 01:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2026 07:23:14 PM
- U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) • PR Newswire (US) • 02/28/2026 01:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 01:49:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 01:39:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 01:31:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 01:28:58 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2026 06:59:04 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 05:30:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2026 03:18:05 PM
- BioMarin to Participate in Four Upcoming Investor Conferences in March • PR Newswire (US) • 02/24/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:08:42 PM
- BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results • PR Newswire (US) • 02/23/2026 09:05:00 PM
- BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET • PR Newswire (US) • 02/17/2026 02:00:00 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2026 12:01:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 09:11:27 PM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
